In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Snapshot evaluation of heart failure in Turkey: baseline characteristics of SELFIE-TR

Session Poster Session 1

Speaker Mehmet Birhan Yilmaz

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure – Epidemiology, Prognosis, Outcome
  • Session type : Poster Session

Authors : A Celik (Mersin,TR), MB Yilmaz (Izmir,TR)

Authors:
A Celik1 , MB Yilmaz2 , 1Mersin University - Mersin - Turkey , 2Dokuz Eylul University - Izmir - Turkey ,

On behalf: SELFIE-TR Investigators

Citation:

Objective: The prevalence of heart failure (HF) in our country was found to be 2.9%. However, country-wise profile, frequency and characteristics of different phenotypes,risk factors are not well established. Hence, it is important to identify phenotypes, risk factors and prescription patterns in a sample representative of Turkey.
Method: Twenty threee centers having at least two cardiologists in charge of patients, out of 12 NUTS-1 regions of Turkey were allowed to make consecutive enrolment for heart failure patients, confirmed by principal investigator according to the guidelines and in pre-selected one-day of each week of October or November (2015).
Results: Whole cohort has mean age of 63.3±13.3 years (M/F ratio: 751/353, % 71.3 / %28.7). In the whole cohort, number of acute and chronic HF patients were 712 and 342. Figure 1 shows the ratio of patients with different HF types. Baseline characteristics of patients with HF were summarized in Table 1. In the whole cohort, hypertension was observed in 46%, diabetes mellitus was present in 27.5%, chronic obstructive pulmonary disease was present in 12.8% and previous myocardial infarction was noted in 45.2%. In patients with HFrEF, ACEI/ARB, beta blocker and MRA use was noted in 74.7%, 89.7%  and 60.9% respectively.
Conclusion: SELFIE-TR provides important insight since it is the first study to show snapshot of heart failure patients in our country. These information might be beneficial to develop guideline-concordant prevention and treatment strategies.

HFrEF (n=801)

HFmrEF(n=176)

HFpEF (n= 77)

P

Age

62,1± 13,2

65,9± 12,3

69,2±14,0

<0,001

Female (%)

26,1

32,4

48,1

<0,001

Acute HF (%)

20,3

20,5

37,7

0,005

Ischemic etiology (%)

52,8

58,5

40,3

0,632

LBBB (%)

31,5

14,9

9,3

<0,001

Hemoglobin (g/dL)

13,0±1,96

12,7±2,0

12,3±2,4

0,013

Creatinin (mg/dL)

1,22±0,59

1,21±0,75

1,15±0,54

0,677

SBP(mmHg)

119±19

121±16

127±17

0,003

HR

80±16

77±16

87±20

0,001

LVEF %

27,4±6,5

42,8±2,8

56,1±5,3

<0,001

LA(mm)

46,1±7,5

42,7±7,5

44,3±8,1

<0,001

TAPSE (mm)

17,8±4,3

20,2±6,5

22,1±5,6

<0,001

esPAB(mmHg)

42,7±14,2

39,5±14,2

42,4±14,3

0,010

Baseline characteristics of patients

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are